237 related articles for article (PubMed ID: 28487953)
1. Interleukin‑6 induces an epithelial‑mesenchymal transition phenotype in human adamantinomatous craniopharyngioma cells and promotes tumor cell migration.
Zhou J; Zhang C; Pan J; Chen L; Qi ST
Mol Med Rep; 2017 Jun; 15(6):4123-4131. PubMed ID: 28487953
[TBL] [Abstract][Full Text] [Related]
2. Periostin activates pathways involved in epithelial-mesenchymal transition in adamantinomatous craniopharyngioma.
Chen M; Zheng SH; Liu Y; Shi J; Qi ST
J Neurol Sci; 2016 Jan; 360():49-54. PubMed ID: 26723972
[TBL] [Abstract][Full Text] [Related]
3. Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin.
Stache C; Bils C; Fahlbusch R; Flitsch J; Buchfelder M; Stefanits H; Czech T; Gaipl U; Frey B; Buslei R; Hölsken A
Neurosurg Focus; 2016 Dec; 41(6):E14. PubMed ID: 27903123
[TBL] [Abstract][Full Text] [Related]
4. Differential Expression of Stem Cell Markers in Human Adamantinomatous Craniopharyngioma and Pituitary Adenoma.
Chang CV; Araujo RV; Cirqueira CS; Cani CM; Matushita H; Cescato VA; Fragoso MC; Bronstein MD; Zerbini MC; Mendonca BB; Carvalho LR
Neuroendocrinology; 2017; 104(2):183-193. PubMed ID: 27161333
[TBL] [Abstract][Full Text] [Related]
5. Molecular Analyses Reveal Inflammatory Mediators in the Solid Component and Cyst Fluid of Human Adamantinomatous Craniopharyngioma.
Donson AM; Apps J; Griesinger AM; Amani V; Witt DA; Anderson RCE; Niazi TN; Grant G; Souweidane M; Johnston JM; Jackson EM; Kleinschmidt-DeMasters BK; Handler MH; Tan AC; Gore L; Virasami A; Gonzalez-Meljem JM; Jacques TS; Martinez-Barbera JP; Foreman NK; Hankinson TC;
J Neuropathol Exp Neurol; 2017 Sep; 76(9):779-788. PubMed ID: 28859336
[TBL] [Abstract][Full Text] [Related]
6. Does the calcification of adamantinomatous craniopharyngioma resemble the calcium deposition of osteogenesis/odontogenesis?
Song-Tao Q; Xiao-Rong Y; Jun P; Yong-Jian D; Jin L; Guang-Long H; Yun-Tao L; Jian R; Xiang-Zhao L; Jia-Ming X
Histopathology; 2014 Feb; 64(3):336-47. PubMed ID: 24387671
[TBL] [Abstract][Full Text] [Related]
7. Tumour compartment transcriptomics demonstrates the activation of inflammatory and odontogenic programmes in human adamantinomatous craniopharyngioma and identifies the MAPK/ERK pathway as a novel therapeutic target.
Apps JR; Carreno G; Gonzalez-Meljem JM; Haston S; Guiho R; Cooper JE; Manshaei S; Jani N; Hölsken A; Pettorini B; Beynon RJ; Simpson DM; Fraser HC; Hong Y; Hallang S; Stone TJ; Virasami A; Donson AM; Jones D; Aquilina K; Spoudeas H; Joshi AR; Grundy R; Storer LCD; Korbonits M; Hilton DA; Tossell K; Thavaraj S; Ungless MA; Gil J; Buslei R; Hankinson T; Hargrave D; Goding C; Andoniadou CL; Brogan P; Jacques TS; Williams HJ; Martinez-Barbera JP
Acta Neuropathol; 2018 May; 135(5):757-777. PubMed ID: 29541918
[TBL] [Abstract][Full Text] [Related]
8. Calretinin is expressed in the stroma of adamantinomatous craniopharyngioma and may induce calcification.
Chaohu W; Yi L; Hai H; Hui Z; Jun P; Song-Tao Q
Clin Neurol Neurosurg; 2015 Nov; 138():124-8. PubMed ID: 26319618
[TBL] [Abstract][Full Text] [Related]
9. Clinical and prognostic role of annexin A2 in adamantinomatous craniopharyngioma.
Wang Y; Deng J; Guo G; Tong A; Peng X; Chen H; Xu J; Liu Y; You C; Zhou L
J Neurooncol; 2017 Jan; 131(1):21-29. PubMed ID: 27640198
[TBL] [Abstract][Full Text] [Related]
10. Adamantinomatous craniopharyngioma cyst fluid can trigger inflammatory activation of microglia to damage the hypothalamic neurons by inducing the production of β-amyloid.
Ainiwan Y; Chen Y; Mao C; Peng J; Chen S; Wei S; Qi S; Pan J
J Neuroinflammation; 2022 May; 19(1):108. PubMed ID: 35525962
[TBL] [Abstract][Full Text] [Related]
11. Multiplexed immunofluorescence reveals potential PD-1/PD-L1 pathway vulnerabilities in craniopharyngioma.
Coy S; Rashid R; Lin JR; Du Z; Donson AM; Hankinson TC; Foreman NK; Manley PE; Kieran MW; Reardon DA; Sorger PK; Santagata S
Neuro Oncol; 2018 Jul; 20(8):1101-1112. PubMed ID: 29509940
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical expression of ErbB2 in adamantinomatous craniopharyngiomas: a possible target for immunotherapy.
Zuhur SS; Tanik C; Erol RS; Musluman AM; Kabukcuoglu F; Altuntas Y
Turk Neurosurg; 2013; 23(1):55-60. PubMed ID: 23344868
[TBL] [Abstract][Full Text] [Related]
13. Epithelial-mesenchymal transition and clinicopathological correlation in craniopharyngioma.
Qi ST; Zhou J; Pan J; Zhang C; Silky C; Yan XR
Histopathology; 2012 Oct; 61(4):711-25. PubMed ID: 23551434
[TBL] [Abstract][Full Text] [Related]
14. Interleukin-1α leads to growth hormone deficiency in adamantinomatous craniopharyngioma by targeting pericytes: implication in pituitary fibrosis.
Mao J; Qiu B; Mei F; Liu F; Feng Z; Fan J; Nie J; Huang L; Liao X; Wang Z; Zeng J; Weng Z; Zang N; Qi S; Bao Y
Metabolism; 2019 Dec; 101():153998. PubMed ID: 31666193
[TBL] [Abstract][Full Text] [Related]
15. [Expression pattern of inflammatory cytokines at various inflammatory levels of adamantinomatous craniopharyngioma].
Zhou J; Qi ST; Chen LG; Huang CR; You J; Zhang C; Pan J
Zhonghua Yi Xue Za Zhi; 2013 Aug; 93(31):2499-501. PubMed ID: 24300275
[TBL] [Abstract][Full Text] [Related]
16. Osteoblastic differentiation and cell calcification of adamantinomatous craniopharyngioma induced by bone morphogenetic protein-2.
Yan X; Kang D; Pan J; Jiang C; Lin Y; Qi S
Cancer Biomark; 2017; 18(2):191-198. PubMed ID: 27983534
[TBL] [Abstract][Full Text] [Related]
17. Possible linkage between specific histological structures and aberrant reactivation of the Wnt pathway in adamantinomatous craniopharyngioma.
Kato K; Nakatani Y; Kanno H; Inayama Y; Ijiri R; Nagahara N; Miyake T; Tanaka M; Ito Y; Aida N; Tachibana K; Sekido K; Tanaka Y
J Pathol; 2004 Jul; 203(3):814-21. PubMed ID: 15221941
[TBL] [Abstract][Full Text] [Related]
18. High expression levels of CXCL12 and CXCR4 predict recurrence of adamanti-nomatous craniopharyngiomas in children.
Gong J; Zhang H; Xing S; Li C; Ma Z; Jia G; Hu W
Cancer Biomark; 2014; 14(4):241-51. PubMed ID: 24934367
[TBL] [Abstract][Full Text] [Related]
19. Expression of interleukin-6 is associated with epithelial-mesenchymal transition and survival rates in gallbladder cancer.
Zhang M; Gong W; Zhang Y; Yang Y; Zhou D; Weng M; Qin Y; Jiang A; Ma F; Quan Z
Mol Med Rep; 2015 May; 11(5):3539-46. PubMed ID: 25573292
[TBL] [Abstract][Full Text] [Related]
20. Adamantinomatous craniopharyngioma: moving toward targeted therapies.
Hengartner AC; Prince E; Vijmasi T; Hankinson TC
Neurosurg Focus; 2020 Jan; 48(1):E7. PubMed ID: 31896087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
